We have observed
4 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after February 23, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN -RELATED PROTEIN 6 (LRP6) ANTIBODIES
COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) MULTIVALENT ANTIBODIES
METHODS OF TREATING FGF21-ASSOCIATED DISORDERS